

Human iPSC-Derived Cardiomyocytes Are Susceptible to

Cell Reports Medicine

1, 100052

DOI: [10.1016/j.xcrm.2020.100052](https://doi.org/10.1016/j.xcrm.2020.100052)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Cardiac inflammation in COVID-19: Lessons from heart failure. <i>Life Sciences</i> , 2020, 260, 118482.	2.0	72
2	Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes. <i>Antiviral Research</i> , 2020, 184, 104955.	1.9	62
3	Role of angiotensin-converting enzyme 2 and pericytes in cardiac complications of COVID-19 infection. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2020, 319, H1059-H1068.	1.5	39
4	COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. <i>Nature Reviews Cardiology</i> , 2020, 17, 543-558.	6.1	999
5	Modeling Multi-organ Infection by SARS-CoV-2 Using Stem Cell Technology. <i>Cell Stem Cell</i> , 2020, 27, 859-868.	5.2	27
6	Cardiovascular Manifestations of COVID-19 Infection. <i>Cells</i> , 2020, 9, 2508.	1.8	142
7	ACE2 Interaction Networks in COVID-19: A Physiological Framework for Prediction of Outcome in Patients with Cardiovascular Risk Factors. <i>Journal of Clinical Medicine</i> , 2020, 9, 3743.	1.0	74
8	Cholesterol 25-hydroxylase suppresses SARS-CoV-2 replication by blocking membrane fusion. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 32105-32113.	3.3	192
9	Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa500.	0.4	38
10	Acute portal vein thrombosis secondary to COVID-19: a case report. <i>BMC Gastroenterology</i> , 2020, 20, 386.	0.8	19
11	COVID-19: A Review on Diagnosis, Treatment, and Prophylaxis. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5145.	1.8	18
12	Noncoding RNAs implication in cardiovascular diseases in the COVID-19 era. <i>Journal of Translational Medicine</i> , 2020, 18, 408.	1.8	16
13	Understanding the complexities of SARS-CoV2 infection and its immunology: A road to immune-based therapeutics. <i>International Immunopharmacology</i> , 2020, 88, 106980.	1.7	31
14	Anticipating the long-term cardiovascular effects of COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 512-524.	1.0	85
15	Cardiovascular Complications Associated with COVID-19 and Potential Therapeutic Strategies. <i>International Journal of Molecular Sciences</i> , 2020, 21, 6790.	1.8	52
16	Sex differences underlying preexisting cardiovascular disease and cardiovascular injury in COVID-19. <i>Journal of Molecular and Cellular Cardiology</i> , 2020, 148, 25-33.	0.9	26
17	Targeting the sAC-Dependent cAMP Pool to Prevent SARS-Cov-2 Infection. <i>Cells</i> , 2020, 9, 1962.	1.8	12
18	Infection of Brain Organoids and 2D Cortical Neurons with SARS-CoV-2 Pseudovirus. <i>Viruses</i> , 2020, 12, 1004.	1.5	53

#	ARTICLE	IF	CITATIONS
19	MicroRNAs targeting the SARS-CoV-2 entry receptor ACE2 in cardiomyocytes. <i>Journal of Molecular and Cellular Cardiology</i> , 2020, 148, 46-49.	0.9	85
20	Clinical characteristics of 41 patients with pneumonia due to 2019 novel coronavirus disease (COVID-19) in Jilin, China. <i>BMC Infectious Diseases</i> , 2020, 20, 961.	1.3	9
21	Pandemic Perspective: Commonalities Between COVID-19 and Cardio-Oncology. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 568720.	1.1	5
22	Immune Mechanisms in Cardiovascular Diseases Associated With Viral Infection. <i>Frontiers in Immunology</i> , 2020, 11, 570681.	2.2	29
23	COVID-19 update: Covid-19-associated coagulopathy. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 54-67.	1.0	529
24	Novel insights on the pulmonary vascular consequences of COVID-19. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2020, 319, L277-L288.	1.3	125
25	Direct SARS-CoV-2 infection of the heart potentiates the cardiovascular sequelae of COVID-19. <i>Drug Discovery Today</i> , 2020, 25, 1559-1560.	3.2	15
26	Proof of SARS-CoV-2 genomes in endomyocardial biopsy with latency after acute infection. <i>International Journal of Infectious Diseases</i> , 2021, 102, 70-72.	1.5	23
27	A review of COVID-19 biomarkers and drug targets: resources and tools. <i>Briefings in Bioinformatics</i> , 2021, 22, 701-713.	3.2	20
28	Coronavirus Disease 2019-associated Thrombosis and Coagulopathy: Review of the Pathophysiological Characteristics and Implications for Antithrombotic Management. <i>Journal of the American Heart Association</i> , 2021, 10, e019650.	1.6	122
29	Using Cardiovascular Cells from Human Pluripotent Stem Cells for COVID-19 Research: Why the Heart Fails. <i>Stem Cell Reports</i> , 2021, 16, 385-397.	2.3	25
30	ApoE-Isoform-Dependent SARS-CoV-2 Neurotropism and Cellular Response. <i>Cell Stem Cell</i> , 2021, 28, 331-342.e5.	5.2	156
31	Cardiac Troponin I association with critical illness and death risk in 726 seriously ill COVID-19 patients: A retrospective cohort study. <i>International Journal of Medical Sciences</i> , 2021, 18, 1474-1483.	1.1	16
32	Cardiovascular disease in SARS-CoV-2 infection. <i>Clinical and Translational Immunology</i> , 2021, 10, e1343.	1.7	28
33	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2): a Systemic Infection. <i>Clinical Microbiology Reviews</i> , 2021, 34, .	5.7	136
34	Human stem cell models to study host-virus interactions in the central nervous system. <i>Nature Reviews Immunology</i> , 2021, 21, 441-453.	10.6	35
35	Remdesivir induces persistent mitochondrial and structural damage in human induced pluripotent stem cell-derived cardiomyocytes. <i>Cardiovascular Research</i> , 2022, 118, 2652-2664.	1.8	20
36	Human induced pluripotent stem cells as a tool for disease modeling and drug screening for COVID-19. <i>Genetics and Molecular Biology</i> , 2021, 44, e20200198.	0.6	3

#	ARTICLE	IF	CITATIONS
37	Expression of Endogenous Angiotensin-Converting Enzyme 2 in Human Induced Pluripotent Stem Cell-Derived Retinal Organoids. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1320.	1.8	28
38	Is COVID-19 Gender-sensitive?. <i>Journal of NeuroImmune Pharmacology</i> , 2021, 16, 38-47.	2.1	123
39	Ex uno, pluresâ€œFrom One Tissue to Many Cells: A Review of Single-Cell Transcriptomics in Cardiovascular Biology. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2071.	1.8	2
41	Experimental Models of SARS-CoV-2 Infection: Possible Platforms to Study COVID-19 Pathogenesis and Potential Treatments. <i>Annual Review of Pharmacology and Toxicology</i> , 2022, 62, 25-53.	4.2	20
42	The Epidemiological and Mechanistic Understanding of the Neurological Manifestations of COVID-19: A Comprehensive Meta-Analysis and a Network Medicine Observation. <i>Frontiers in Neuroscience</i> , 2021, 15, 606926.	1.4	6
43	SARS-CoV-2 Infection and Disease Modelling Using Stem Cell Technology and Organoids. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2356.	1.8	13
44	In vitro and In silico Models to Study SARS-CoV-2 Infection: Integrating Experimental and Computational Tools to Mimic â€œCOVID-19 Cardiomyocyteâ€œ. <i>Frontiers in Physiology</i> , 2021, 12, 624185.	1.3	7
46	COVID-19: The Heart of the Matterâ€œPathological Changes and a Proposed Mechanism. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2021, 26, 217-224.	1.0	9
47	SARS-CoV-2 infection rewires host cell metabolism and is potentially susceptible to mTORC1 inhibition. <i>Nature Communications</i> , 2021, 12, 1876.	5.8	88
48	Clofazimine broadly inhibits coronaviruses including SARS-CoV-2. <i>Nature</i> , 2021, 593, 418-423.	13.7	151
49	Impact of Cardiovascular Diseases on COVID-19: A Systematic Review. <i>Medical Science Monitor</i> , 2021, 27, e930032.	0.5	4
50	A Perspective on Personalized Therapies in Hypertrophic Cardiomyopathy. <i>Journal of Cardiovascular Pharmacology</i> , 2021, 77, 317-322.	0.8	7
51	Factors associated with myocardial SARS-CoV-2 infection, myocarditis, and cardiac inflammation in patients with COVID-19. <i>Modern Pathology</i> , 2021, 34, 1345-1357.	2.9	90
52	Integrated Bioinformatic Analysis of SARS-CoV-2 Infection Related Genes ACE2, BSG and TMPRSS2 in Aerodigestive Cancers. <i>Journal of Inflammation Research</i> , 2021, Volume 14, 791-802.	1.6	15
53	Cardiovascular Injury Due to SARS-CoV-2. <i>Current Clinical Microbiology Reports</i> , 2021, 8, 167-177.	1.8	18
54	SARS-CoV-2 Infects Human Pluripotent Stem Cell-Derived Cardiomyocytes, Impairing Electrical and Mechanical Function. <i>Stem Cell Reports</i> , 2021, 16, 478-492.	2.3	75
55	Right Ventricular Strain Is Common in Intubated COVID-19 Patients and Does Not Reflect Severity of Respiratory Illness. <i>Journal of Intensive Care Medicine</i> , 2021, 36, 900-909.	1.3	27
56	Toward the Effective Bioengineering of a Pathological Tissue for Cardiovascular Disease Modeling: Old Strategies and New Frontiers for Prevention, Diagnosis, and Therapy. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 591583.	1.1	3

#	ARTICLE	IF	CITATIONS
57	Network pharmacology and RNA-sequencing reveal the molecular mechanism of Xuebijing injection on COVID-19-induced cardiac dysfunction. <i>Computers in Biology and Medicine</i> , 2021, 131, 104293.	3.9	14
58	Repositioned Drugs for COVID-19—the Impact on Multiple Organs. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 1484-1501.	0.3	3
59	Aspirin Resistance in Obese and Elderly Patients with COVID-19?. <i>American Journal of Medicine</i> , 2021, 134, e297.	0.6	1
60	BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection. <i>Cell</i> , 2021, 184, 2167-2182.e22.	13.5	131
61	Management of COVID-19-associated multisystem inflammatory syndrome in children: A comprehensive literature review. <i>Progress in Pediatric Cardiology</i> , 2021, 63, 101381.	0.2	11
62	The Essential Vulnerability of Human Cardiac Myocytes to SARS-CoV-2. <i>JACC Basic To Translational Science</i> , 2021, 6, 346-349.	1.9	4
63	Cell-free DNA maps COVID-19 tissue injury and risk of death and can cause tissue injury. <i>JCI Insight</i> , 2021, 6, .	2.3	86
64	Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication. <i>Cell Reports</i> , 2021, 35, 108940.	2.9	76
66	Portal Vein Thrombosis—a Rare Complication of SARS-CoV-2 Infection. <i>SN Comprehensive Clinical Medicine</i> , 2021, 3, 1416-1419.	0.3	5
67	An Immuno-Cardiac Model for Macrophage-Mediated Inflammation in COVID-19 Hearts. <i>Circulation Research</i> , 2021, 129, 33-46.	2.0	40
68	SARS-CoV-2 induces double-stranded RNA-mediated innate immune responses in respiratory epithelial-derived cells and cardiomyocytes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	159
69	SARS-CoV-2 infection of human iPSC-derived cardiac cells reflects cytopathic features in hearts of patients with COVID-19. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	143
70	COVID-19 and Cardiovascular Disease. <i>Circulation Research</i> , 2021, 128, 1214-1236.	2.0	232
71	In vitro safety and clinical trial of the cardiac liability of drug polytherapy. <i>Clinical and Translational Science</i> , 2021, 14, 1155-1165.	1.5	11
72	Human stem cell-based models for studying host-pathogen interactions. <i>Cellular Microbiology</i> , 2021, 23, e13335.	1.1	13
73	Coronary Vasculitis. <i>Biomedicines</i> , 2021, 9, 622.	1.4	17
74	Modeling Precision Cardio-Oncology: Using Human-Induced Pluripotent Stem Cells for Risk Stratification and Prevention. <i>Current Oncology Reports</i> , 2021, 23, 77.	1.8	2
75	Pulmonary Edema in COVID-19 Patients: Mechanisms and Treatment Potential. <i>Frontiers in Pharmacology</i> , 2021, 12, 664349.	1.6	44

#	ARTICLE	IF	CITATIONS
76	COVID-19-related cardiac complications from clinical evidences to basic mechanisms: opinion paper of the ESC Working Group on Cellular Biology of the Heart. <i>Cardiovascular Research</i> , 2021, 117, 2148-2160.	1.8	26
77	Progress in cardiac research: from rebooting cardiac regeneration to a complete cell atlas of the heart. <i>Cardiovascular Research</i> , 2021, 117, 2161-2174.	1.8	23
79	Macrophages: Potential Therapeutic Target of Myocardial Injury in COVID-19. <i>Circulation Research</i> , 2021, 129, 47-49.	2.0	2
80	Deleterious Effects of SARS-CoV-2 Infection on Human Pancreatic Cells. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 678482.	1.8	40
81	Human Kidney Spheroids and Monolayers Provide Insights into SARS-CoV-2 Renal Interactions. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2242-2254.	3.0	24
82	Human embryonic stem cell-derived cardiomyocyte platform screens inhibitors of SARS-CoV-2 infection. <i>Communications Biology</i> , 2021, 4, 926.	2.0	11
83	Unraveling the molecular crosstalk between Atherosclerosis and COVID-19 comorbidity. <i>Computers in Biology and Medicine</i> , 2021, 134, 104459.	3.9	18
84	Identifying COVID-19-Specific Transcriptomic Biomarkers with Machine Learning Methods. <i>BioMed Research International</i> , 2021, 2021, 1-11.	0.9	17
86	Imaging Evaluation of Pulmonary and Non-Ischaemic Cardiovascular Manifestations of COVID-19. <i>Diagnostics</i> , 2021, 11, 1271.	1.3	8
89	Heart injury in COVID-19: immediate and long-term follow-up. <i>Perm Medical Journal</i> , 2021, 38, 48-60.	0.0	2
90	The SARS-CoV-2/Receptor Axis in Heart and Blood Vessels: A Crisp Update on COVID-19 Disease with Cardiovascular Complications. <i>Viruses</i> , 2021, 13, 1346.	1.5	11
91	Cardiovascular Disease Complicating COVID-19 in the Elderly. <i>Medicina (Lithuania)</i> , 2021, 57, 833.	0.8	9
92	SARS-CoV-2 infection initiates interleukin-17-enriched transcriptional response in different cells from multiple organs. <i>Scientific Reports</i> , 2021, 11, 16814.	1.6	43
93	Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease. <i>PLoS ONE</i> , 2021, 16, e0255335.	1.1	48
95	Human Stem Cell Models of SARS-CoV-2 Infection in the Cardiovascular System. <i>Stem Cell Reviews and Reports</i> , 2021, 17, 2107-2119.	1.7	0
96	Comparative transcriptomic analysis of SARS-CoV-2 infected cell model systems reveals differential innate immune responses. <i>Scientific Reports</i> , 2021, 11, 17146.	1.6	21
97	Stem Cells as a Model of Study of SARS-CoV-2 and COVID-19: A Systematic Review of the Literature. <i>BioMed Research International</i> , 2021, 2021, 1-7.	0.9	3
98	Expression Profiles and Potential Functions of Long Non-Coding RNAs in the Heart of Mice With Coxsackie B3 Virus-Induced Myocarditis. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 704919.	1.8	7

#	ARTICLE	IF	CITATIONS
99	Deciphering pathogenicity of variants of uncertain significance with CRISPR-edited iPSCs. Trends in Genetics, 2021, 37, 1109-1123.	2.9	14
100	Viruses in the Heart: Direct and Indirect Routes to Myocarditis and Heart Failure. Viruses, 2021, 13, 1924.	1.5	12
101	Coronavirus Disease-2019 and Heart Failure: A Scientific Statement From the Heart Failure Society of America. Journal of Cardiac Failure, 2022, 28, 93-112.	0.7	15
102	Cardiovascular implications of the COVID-19 pandemic. Journal of Cardiology, 2022, 79, 460-467.	0.8	7
104	A bioinformatics approach for identifying potential molecular mechanisms and key genes involved in COVID-19 associated cardiac remodeling. Gene Reports, 2021, 24, 101246.	0.4	8
105	Decrypting the role of predicted SARS-CoV-2 miRNAs in COVID-19 pathogenesis: A bioinformatics approach. Computers in Biology and Medicine, 2021, 136, 104669.	3.9	16
106	Tumor Necrosis Factor-Alpha Exacerbates Viral Entry in SARS-CoV2-Infected iPSC-Derived Cardiomyocytes. International Journal of Molecular Sciences, 2021, 22, 9869.	1.8	11
107	Antihypertensive drug treatment and susceptibility to SARS-CoV-2 infection in human PSC-derived cardiomyocytes and primary endothelial cells. Stem Cell Reports, 2021, 16, 2459-2472.	2.3	11
108	Cardiomyocytes recruit monocytes upon SARS-CoV-2 infection by secreting ACCL2. Stem Cell Reports, 2021, 16, 2274-2288.	2.3	37
109	SARS-CoV-2 Disrupts Proximal Elements in the JAK-STAT Pathway. Journal of Virology, 2021, 95, e0086221.	1.5	58
110	BOAT1 Amino Acid Transporter Complexed With SARS-CoV-2 Receptor ACE2 Forms a Heterodimer Functional Unit: <i>In Situ</i> Conformation Using Radiation Inactivation Analysis. Function, 2021, 2, zqab027.	1.1	13
111	Generation of SARS-CoV-2 Spike Pseudotyped Virus for Viral Entry and Neutralization Assays: A 1-Week Protocol. Frontiers in Cardiovascular Medicine, 2020, 7, 618651.	1.1	60
112	Dysregulation of the mevalonate pathway during SARS-CoV-2 infection: An in silico study. Journal of Medical Virology, 2021, 93, 2396-2405.	2.5	12
125	Role of Cardiac Macrophages on Cardiac Inflammation, Fibrosis and Tissue Repair. Cells, 2021, 10, 51.	1.8	159
126	Extrapulmonary Clinical Manifestations in COVID-19 Patients. American Journal of Tropical Medicine and Hygiene, 2020, 103, 1783-1796.	0.6	59
127	Acute and Chronic Effects of COVID-19 on the Cardiovascular System. Journal of Cardiovascular Development and Disease, 2021, 8, 128.	0.8	16
128	SARS-CoV-2 exploits host DGAT and ADRP for efficient replication. Cell Discovery, 2021, 7, 100.	3.1	29
130	Recent Advances of COVID-19 Modeling Based on Regenerative Medicine. Frontiers in Cell and Developmental Biology, 2021, 9, 683619.	1.8	8

#	ARTICLE	IF	CITATIONS
131	Cardiotoxicity of Antineoplastic Therapies and Applications of Induced Pluripotent Stem Cell-Derived Cardiomyocytes. <i>Cells</i> , 2021, 10, 2823.	1.8	7
132	Highly Efficient SARS-CoV-2 Infection of Human Cardiomyocytes: Spike Protein-Mediated Cell Fusion and Its Inhibition. <i>Journal of Virology</i> , 2021, 95, e0136821.	1.5	29
133	The Role of the Immune System on the Cardiac Complications Observed in SARS-CoV-2. <i>International Journal of Cardiovascular Sciences</i> , 2021, , .	0.0	0
134	WIN 55,212-2 shows anti-inflammatory and survival properties in human iPSC-derived cardiomyocytes infected with SARS-CoV-2. <i>PeerJ</i> , 2021, 9, e12262.	0.9	5
135	COVID-19: The Cause of the Manifested Cardiovascular Complications During the Pandemic. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 744482.	1.1	3
136	Inter-kingdom regulation of human transcriptome by dietary microRNAs: Emerging bioactives from edible plants to treat human diseases?. <i>Trends in Food Science and Technology</i> , 2021, 118, 723-723.	7.8	2
137	Are Aspirin and Apixaban Sufficient to Prevent Immunothrombosis in COVID-19?. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
138	Kidney in the net of acute and long-haul coronavirus disease 2019: a potential role for lipid mediators in causing renal injury and fibrosis. <i>Current Opinion in Nephrology and Hypertension</i> , 2022, 31, 36-46.	1.0	11
139	Functional Effects of Cardiomyocyte Injury in COVID-19. <i>Journal of Virology</i> , 2022, 96, JVI0106321.	1.5	17
140	COVID-19, the Pandemic of the Century and Its Impact on Cardiovascular Diseases. <i>Cardiology Discovery</i> , 2021, 1, 233-258.	0.6	6
141	Application of the Pluripotent Stem Cells and Genomics in Cardiovascular Researchâ€”What We Have Learnt and Not Learnt until Now. <i>Cells</i> , 2021, 10, 3112.	1.8	4
142	Emerging technologies and their impact on regulatory science. <i>Experimental Biology and Medicine</i> , 2022, 247, 1-75.	1.1	22
144	Co-Regulation of Protein Coding Genes by Transcription Factor and Long Non-Coding RNA in SARS-CoV-2 Infected Cells: An In Silico Analysis. <i>Non-coding RNA</i> , 2021, 7, 74.	1.3	5
145	When stem cells meet COVID-19: recent advances, challenges and future perspectives. <i>Stem Cell Research and Therapy</i> , 2022, 13, 9.	2.4	9
146	Inflammatory activation and immune cell infiltration are main biological characteristics of SARS-CoV-2 infected myocardium. <i>Bioengineered</i> , 2022, 13, 2486-2497.	1.4	5
147	Induced pluripotent stem cells. , 2022, , 1-58.		0
148	Ramatroban for chemoprophylaxis and treatment of COVID-19: David takes on Goliath. <i>Expert Opinion on Therapeutic Targets</i> , 2022, 26, 13-28.	1.5	5
149	Network analysis of host-pathogen protein interactions in microbe induced cardiovascular diseases. <i>In Silico Biology</i> , 2022, 14, 115-133.	0.4	1

#	ARTICLE	IF	CITATIONS
150	Molecular Mechanisms of Cardiac Injury Associated With Myocardial SARS-CoV-2 Infection. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 643958.	1.1	10
152	Oxidative stress and inflammatory markers in patients with COVID-19: Potential role of RAGE, HMGB1, GFAP and COX-2 in disease severity. <i>International Immunopharmacology</i> , 2022, 104, 108502.	1.7	30
155	Treating COVID-19: Evolving approaches to evidence in a pandemic. <i>Cell Reports Medicine</i> , 2022, 3, 100533.	3.3	7
156	The Pathogenesis and Long-Term Consequences of COVID-19 Cardiac Injury. <i>JACC Basic To Translational Science</i> , 2022, 7, 294-308.	1.9	58
157	Manifestations and Mechanism of SARS-CoV2 Mediated Cardiac Injury. <i>International Journal of Biological Sciences</i> , 2022, 18, 2703-2713.	2.6	13
158	COVID-19 and the Vasculature: Current Aspects and Long-Term Consequences. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 824851.	1.8	51
159	Genome-wide analyses reveal the detrimental impacts of SARS-CoV-2 viral gene Orf9c on human pluripotent stem cell-derived cardiomyocytes. <i>Stem Cell Reports</i> , 2022, 17, 522-537.	2.3	2
160	Cardiovascular Dysfunction in COVID-19: Association Between Endothelial Cell Injury and Lactate. <i>Frontiers in Immunology</i> , 2022, 13, 868679.	2.2	7
161	Organoid Models of SARS-CoV-2 Infection: What Have We Learned about COVID-19?. <i>Organoids</i> , 2022, 1, 2-27.	1.8	12
162	Development of off-the-shelf hematopoietic stem cell-engineered invariant natural killer T cells for COVID-19 therapeutic intervention. <i>Stem Cell Research and Therapy</i> , 2022, 13, 112.	2.4	14
163	A REVIEW ON THE DEVELOPMENT OF FAVIPRAVIR AGAINST SARS COV 2 INFECTION. <i>International Journal of Current Pharmaceutical Research</i> , 0, , 11-14.	0.2	0
164	The pathological maelstrom of COVID-19 and cardiovascular disease. , 2022, 1, 200-210.		14
165	Targeting papain-like protease for broad-spectrum coronavirus inhibition. <i>Protein and Cell</i> , 2022, 13, 940-953.	4.8	23
167	Ferroptosis of Pacemaker Cells in COVID-19. <i>Circulation Research</i> , 2022, 130, 978-980.	2.0	4
168	Understanding on the possible routes for SARS CoV-2 invasion via ACE2 in the host linked with multiple organs damage. <i>Infection, Genetics and Evolution</i> , 2022, 99, 105254.	1.0	21
169	Inhibition of SARS-CoV-2 infection in human iPSC-derived cardiomyocytes by targeting the Sigma-1 receptor disrupts cytoarchitecture and beating. <i>PeerJ</i> , 2021, 9, e12595.	0.9	5
170	Myocardial damage in new coronavirus infection (review). <i>Bulletin Physiology and Pathology of Respiration</i> , 2021, , 129-145.	0.0	1
171	Use of the Genus <i>Satureja</i> as Food Supplement: Possible Modulation of the Immune System <i>via</i> Intestinal Microbiota During SARS-CoV-2 Infection. <i>Anti-Infective Agents</i> , 2022, 20, .	0.1	0

#	ARTICLE	IF	CITATIONS
172	ER Stress in COVID-19 and Parkinson's Disease: In Vitro and In Silico Evidences. <i>Brain Sciences</i> , 2022, 12, 507.	1.1	4
173	SARS-CoV-2 Employ BSG/CD147 and ACE2 Receptors to Directly Infect Human Induced Pluripotent Stem Cell-Derived Kidney Podocytes. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 855340.	1.8	23
175	The S Protein of SARS-CoV-2 Injures Cardiomyocytes Indirectly through the Release of Cytokines Instead of Direct Action. <i>Acta Cardiologica Sinica</i> , 2021, 37, 643-647.	0.1	0
176	SARS-CoV-2 Spike Protein-Induced Damage of hiPSC-Derived Cardiomyocytes. <i>Advanced Biology</i> , 2022, 6, e2101327.	1.4	8
177	Multiple Sclerosis Biomarker Candidates Revealed by Cell-Type-Specific Interactome Analysis. <i>OMICS A Journal of Integrative Biology</i> , 2022, 26, 305-317.	1.0	2
178	SARS-CoV-2 infects human cardiomyocytes promoted by inflammation and oxidative stress. <i>International Journal of Cardiology</i> , 2022, 362, 196-205.	0.8	9
179	Myocardial Injury in COVID-19 and Its Implications in Short- and Long-Term Outcomes. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, .	1.1	9
180	Spatial region-resolved proteome map reveals mechanism of COVID-19-associated heart injury. <i>Cell Reports</i> , 2022, 39, 110955.	2.9	16
181	Modeling Nonischemic Genetic Cardiomyopathies Using Induced Pluripotent Stem Cells. <i>Current Cardiology Reports</i> , 2022, 24, 631-644.	1.3	2
182	Identification of critical genes and molecular pathways in COVID-19 myocarditis and constructing gene regulatory networks by bioinformatic analysis. <i>PLoS ONE</i> , 2022, 17, e0269386.	1.1	6
183	Tissue repair strategies: What we have learned from COVID-19 in the application of MSCs therapy. <i>Pharmacological Research</i> , 2022, 182, 106334.	3.1	2
184	Accelerating cardiovascular research: recent advances in translational 2D and 3D heart models. <i>European Journal of Heart Failure</i> , 2022, 24, 1778-1791.	2.9	11
185	Thrombosis-related circulating miR-16-5p is associated with disease severity in patients hospitalised for COVID-19. <i>RNA Biology</i> , 2022, 19, 963-979.	1.5	11
186	Peroxisomal very long-chain fatty acid transport is targeted by herpesviruses and the antiviral host response. <i>Communications Biology</i> , 2022, 5, .	2.0	6
188	Macrophage, a potential targeted therapeutic immune cell for cardiomyopathy. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	4
189	Modeling Cardiac SARS-CoV-2 Infection with Human Pluripotent Stem Cells. <i>Current Cardiology Reports</i> , 2022, 24, 2121-2129.	1.3	1
190	SARS-CoV-2 cellular tropism and direct multiorgan failure in COVID-19 patients: Bioinformatic predictions, experimental observations, and open questions. <i>Cell Biology International</i> , 2023, 47, 308-326.	1.4	7
191	Viral and Host Small RNA Response to SARS-CoV-2 Infection. <i>Microbiology Research</i> , 2022, 13, 788-808.	0.8	1

#	ARTICLE	IF	CITATIONS
192	Endothelial Dysfunction in COVID-19: Potential Mechanisms and Possible Therapeutic Options. <i>Life</i> , 2022, 12, 1605.	1.1	12
193	Enhanced metanephric specification to functional proximal tubule enables toxicity screening and infectious disease modelling in kidney organoids. <i>Nature Communications</i> , 2022, 13, .	5.8	27
194	Hippo signaling pathway activation during SARS-CoV-2 infection contributes to host antiviral response. <i>PLoS Biology</i> , 2022, 20, e3001851.	2.6	12
195	Opportunities and Challenges of Human iPSC Technology in Kidney Disease Research. <i>Biomedicines</i> , 2022, 10, 3232.	1.4	0
196	Influenza A virus modulates ACE2 expression and SARS-CoV-2 infectivity in human cardiomyocytes. <i>IScience</i> , 2022, 25, 105701.	1.9	1
197	Cardiac magnetic resonance T2* mapping in patients with COVID-19 pneumonia is associated with serum ferritin level?. <i>International Journal of Cardiovascular Imaging</i> , 0, , .	0.7	0
198	The Role of Advanced Technologies against COVID-19: Prevention, Detection, and Treatments. <i>Current Stem Cell Research and Therapy</i> , 2023, 18, 800-828.	0.6	0
199	TRPC3-Nox2 Protein Complex Formation Increases the Risk of SARS-CoV-2 Spike Protein-Induced Cardiomyocyte Dysfunction through ACE2 Upregulation. <i>International Journal of Molecular Sciences</i> , 2023, 24, 102.	1.8	3
200	Heart rate variability as an indicator of COVID-19 induced myocardial injury: a retrospective cohort study. <i>BMC Anesthesiology</i> , 2023, 23, .	0.7	1
201	Cardiovascular complications of respiratory viral infections. <i>Sibirskij Å¾urnal Kliničeskoj I Å½ksperimental'noj Mediciny</i> , 2023, 37, 31-37.	0.1	0
202	Thrombo-Inflammation in COVID-19 and Sickle Cell Disease: Two Faces of the Same Coin. <i>Biomedicines</i> , 2023, 11, 338.	1.4	3
203	SARS-CoV-2 Establishes a Productive Infection in Hepatoma and Glioblastoma Multiforme Cell Lines. <i>Cancers</i> , 2023, 15, 632.	1.7	3
205	Ectopic expression of SARS-CoV-2 S and ORF-9B proteins alters metabolic profiles and impairs contractile function in cardiomyocytes. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	2
206	SARS-CoV-2 spike protein-mediated cardiomyocyte fusion may contribute to increased arrhythmic risk in COVID-19. <i>PLoS ONE</i> , 2023, 18, e0282151.	1.1	6
207	How Does COVID-19 Affect the Heart?. <i>Current Cardiology Reports</i> , 2023, 25, 171-184.	1.3	7
208	Rhinoorbital mucormycosis in patients with the post-COVID syndrome. Clinical and morphological features. <i>Rossiiskaya Rinologiya</i> , 2023, 31, 66.	0.1	1
209	COVID-19 and Cardiovascular Diseases: From Cellular Mechanisms to Clinical Manifestations. , 2023, 14, 2071.		4
210	A multi-organoid platform identifies CIART as a key factor for SARS-CoV-2 infection. <i>Nature Cell Biology</i> , 2023, 25, 381-389.	4.6	9

#	ARTICLE	IF	CITATIONS
229	Non-Coding RNA-Mediated Gene Regulation in Cardiovascular Disorders: Current Insights and Future Directions. Journal of Cardiovascular Translational Research, 0, , .	1.1	1